
北美寡核苷酸合成市场到 2027 年 - 按产品(合成寡核苷酸、试剂和设备)、应用(研究、诊断和治疗)、最终用户(学术研究机构、制药和生物技术公司、诊断实验室和其他最终用户)
No. of Pages: 134 | Report Code: TIPRE00007127 | Category: Life Sciences
No. of Pages: 134 | Report Code: TIPRE00007127 | Category: Life Sciences
北美寡核苷酸合成市场预计将从 2018 年的 6.099 亿美元增至 2027 年的 15.4103 亿美元。预计该市场将以 11.2% 的复合年增长率增长2019-2027。
市场的增长是由以下因素驱动的: 制药和生物技术公司发展投资的增加、政府机构的资金以及市场参与者数量的增加及其对寡核苷酸合成市场的关注可能会推动寡核苷酸合成的增长
寡核苷酸被用于许多生物应用,因为序列特异性结合剂可以帮助识别是否存在特定的目标 DNA 序列。合成寡核苷酸是短链单链 DNA。寡核苷酸在疾病诊断、生物技术研究、治疗、法医学、药物发现等方面有多种用途。合成寡核苷酸广泛应用于人类遗传疾病的诊断。寡核苷酸探针用于检测人类基因组内的单碱基对变化。例如,由β-珠蛋白基因内的颠换(A^T)引起的镰状细胞性贫血可以用标记的寡核苷酸进行分析。在严格杂交条件下,可以检测家族的一个或两个等位基因是否含有突变基因。
研究人员还利用寡核苷酸来检测产生更高效、更绿色的化学合成。通过将寡核苷酸组装成编码合成基因的较长片段,可以指示细菌或酵母细胞产生特定的酶(一种蛋白质)。
<寡核苷酸还可以促进治疗方法的开发,因为可以靶向、操纵、沉默和/或调节出现故障的基因。例如,Ionis Pharmaceuticals 致力于寡核苷酸治疗药物的开发,特别是反义寡核苷酸 (ASO) 治疗药物。因此,合成寡核苷酸在各个领域的巨大潜力推动了市场的增长。
近年来在加拿大进行了临床试验,预计将促进寡核苷酸合成市场的增长。例如,根据 2019 年 1 月发布的新闻稿,一项 3 期试验正在美国和加拿大招募患有亨廷顿舞蹈症的成年人,以测试研究疗法 RG6042 的潜力。 RG6042最初被称为IONIS-HTTRx,是一种分析型反义寡核苷酸治疗药物,早期由Ionis Pharmaceuticals开发,后来被罗氏收购。它旨在靶向并破坏不同形式的突变亨廷顿蛋白 (mHTT),这是亨廷顿病的主要原因。该试验预计将在加拿大五个省的六个地点进行
; p>
由于专门用于制造公司以及学术和研究机构开发基于基因合成的最终产品的投资和资金不断增加,预计美国将引领北美地区的市场,例如精准医学和其他疗法。因此,考虑到上述因素,在预测期内,该国市场的增长可能会在北美地区贡献最大份额。
图表:到 2027 年墨西哥寡核苷酸合成市场收入和预测(百万美元)
< strong>北美寡核苷酸合成——市场细分
按产品 strong>
< p>
作者
最终用户
按地理位置
公司简介
Strategic insights for North America Oligonucleotide Synthesis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2018 | US$ 609.90 Million |
Market Size by 2027 | US$ $ 1,541.03 Million |
Global CAGR (2019 - 2027) | 11.2% |
Historical Data | 2016-2017 |
Forecast period | 2019-2027 |
Segments Covered |
By 产品
|
Regions and Countries Covered | 北美
|
Market leaders and key company profiles |
The regional scope of North America Oligonucleotide Synthesis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The List of Companies
The North America Oligonucleotide Synthesis Market is valued at US$ 609.90 Million in 2018, it is projected to reach US$ $ 1,541.03 Million by 2027.
As per our report North America Oligonucleotide Synthesis Market, the market size is valued at US$ 609.90 Million in 2018, projecting it to reach US$ $ 1,541.03 Million by 2027. This translates to a CAGR of approximately 11.2% during the forecast period.
The North America Oligonucleotide Synthesis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Oligonucleotide Synthesis Market report:
The North America Oligonucleotide Synthesis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Oligonucleotide Synthesis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Oligonucleotide Synthesis Market value chain can benefit from the information contained in a comprehensive market report.